Search hospitals > Missouri > Kansas City
Children's Mercy Hospital
Claim this profileKansas City, Missouri 64108
Global Leader in Adult T-Cell Leukemia/Lymphoma
Global Leader in Cancer
Conducts research for Acute Lymphoblastic Leukemia
Conducts research for Neuroblastoma
Conducts research for Brain Tumor
841 reported clinical trials
48 medical researchers
Summary
Children's Mercy Hospital is a medical facility located in Kansas City, Missouri. This center is recognized for care of Adult T-Cell Leukemia/Lymphoma, Cancer, Acute Lymphoblastic Leukemia, Neuroblastoma, Brain Tumor and other specialties. Children's Mercy Hospital is involved with conducting 841 clinical trials across 1,119 conditions. There are 48 research doctors associated with this hospital, such as Keith J. August, Kevin F. Ginn, John Anderson, MD, and Mark Clements, MD, PhD.Area of expertise
1Adult T-Cell Leukemia/Lymphoma
Global LeaderStage II
Philadelphia chromosome positive
NTRK1 positive
2Cancer
Global LeaderStage IV
Stage I
Stage II
Top PIs
Keith J. AugustChildren's Mercy Hospitals and Clinics5 years of reported clinical research
Expert in Cystic Tumor
Studies Adult T-Cell Leukemia/Lymphoma
54 reported clinical trials
111 drugs studied
Kevin F. GinnChildren's Mercy Hospitals and Clinics8 years of reported clinical research
Expert in Cancer
Expert in Relapse
36 reported clinical trials
58 drugs studied
John Anderson, MDClinical Research Center of Alabama5 years of reported clinical research
Studies Angioedema
Studies Hereditary Angioedema
9 reported clinical trials
11 drugs studied
Mark Clements, MD, PhDChildren's Mercy Hospital2 years of reported clinical research
Studies Type 1 Diabetes
Studies Diabetes Mellitus
8 reported clinical trials
15 drugs studied
Clinical Trials running at Children's Mercy Hospital
Neuroblastoma
Brain Tumor
Acute Lymphoblastic Leukemia
Testicular cancer
Wilms Tumor
Chronic Kidney Disease
Lymphoma
Lazy Eye
Cancer
Rhabdomyosarcoma
Dinutuximab + Chemotherapy
for High-Risk Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Recruiting2 awards Phase 37 criteria
Advanced Therapy
for Neuroblastoma
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Recruiting1 award Phase 23 criteria
DFMO Maintenance Therapy
for Neuroblastoma
This trial tests a medication called DFMO in patients with high-risk neuroblastoma who are in remission. The goal is to prevent the cancer from returning by stopping an enzyme that cancer cells need to grow. DFMO was initially developed as a cancer therapeutic agent but gained renewed interest as a preventive agent after showing effectiveness in inhibiting cancer development in rodent models.
Recruiting1 award Phase 2
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Children's Mercy Hospital?
Where is Children's Mercy Hospital located?
Who should I call to ask about financial aid or insurance network?
What insurance does Children's Mercy Hospital accept?
What awards or recognition has Children's Mercy Hospital received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.